Ivan Kairatov has spent years at the crossroads of oncology and drug development, translating trial signals into day-to-day decisions for patients with localized prostate cancer. In this conversation, he unpacks new evidence showing that most of the value from androgen deprivation therapy (ADT)
A therapy that should unleash the immune system instead fuels a tumor’s growth, and the only way to see why is to listen to each cell speak for itself; that is the everyday paradox that single-cell RNA sequencing (scRNA-seq) now makes decipherable in real time. In oncology, this shift from average
In cancer trials where survival curves dominate headlines yet leave the lived experience in the margins, a new consensus promises to pull patient voices into the center of decision-making by standardizing how those voices are captured, analyzed, and reported. Patient-reported outcomes (PROs) have
Imagine starting each day with a steaming cup of tea, a ritual cherished by millions worldwide for its soothing aroma and perceived wellness perks. Yet, beneath this comforting habit lies a complex debate: Is tea truly a health elixir, or does it harbor hidden risks? This roundup dives into the
After first-line therapy fails in advanced biliary cancer, the next decision can stretch between hope for extra months and fear of heavy toxicity, a fraught balance that now places FOLFIRINOX squarely under the spotlight. Clinics see this crossroads every week: a patient who just progressed on
In operating rooms where silence often amplifies stress, a small change—a pair of headphones and a vigilant recovery plan—can shift the arc of the first hours after colorectal cancer surgery, easing the path from anesthesia to wakefulness while trimming complications that make families and
